Chi Advisors LLC Prometheus Biosciences, Inc. Transaction History

Chi Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$103.46 - $126.29 $1.07 Million - $1.31 Million	10,335 Added 1.12%	934,135 $100 Million
Q4 2022 Feb 13, 2023	SELL	$36.06 - $117.21 $24.4 Million - $79.5 Million	-677,985 Reduced 42.33%	923,800 $102 Million
Q3 2022 Nov 09, 2022	SELL	$28.17 - $59.01 $1.98 Million - $4.14 Million	-70,191 Reduced 4.2%	1,601,785 $94.5 Million
Q2 2022 Aug 12, 2022	BUY	$22.39 - $38.94 $1.95 Million - $3.38 Million	86,880 Added 5.48%	1,671,976 $47.2 Million
Q1 2022 May 16, 2022	SELL	$30.13 - $50.0 $5.04 Million - $8.36 Million	-167,147 Reduced 9.54%	1,585,096 $59.9 Million
Q4 2021 Feb 11, 2022	SELL	$22.28 - $39.54 $24.7 Million - $43.9 Million	-1,109,816 Reduced 38.78%	1,752,243 $69.3 Million
Q3 2021 Nov 15, 2021	BUY	$20.89 - $26.96 $209,944 - $270,948	10,050 Added 0.35%	2,862,059 $67.9 Million
Q2 2021 Aug 11, 2021	SELL	$16.8 - $29.65 $369,986 - $652,981	-22,023 Reduced 0.77%	2,852,009 $70 Million
Q1 2021 May 14, 2021	BUY	$16.51 - $25.29 $47.5 Million - $72.7 Million	2,874,032 New	2,874,032 $52.5 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Chi Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Chi Advisors LLC with notifications on news.